Research Listing: Tourette Syndrome: Pharmacotherapy and General Therapeutic Approaches



Click on symbol (if present) at end of reference for link:
Abstracts are usually free to view online however many full articles require subscription



​



Tourette disorder treated with valproic acid. Ye L1, Lippmann S. Clin Neuropharmacol. 2014 Jan-Feb;37(1):36-7. doi: 10.1097/WNF.0000000000000013. >>

 

A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Gilbert DL1, Budman CL, Singer HS, Kurlan R, Chipkin RE. Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. doi: 10.1097/WNF.0000000000000017. >>

 

Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Egolf A, Coffey BJ. Drugs Today (Barc). 2014 Feb;50(2):159-79. doi: 10.1358/dot.2014.50.2.2097801. >>

 

Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Pringsheim T, Doja A, Gorman D, et al. Can J Psychiatry 2012 Mar; 57(3):133-43.
 

Canadian guidelines for the evidence-based treatment of tic disorders. Sandor P, Carroll A. Can J Psychiatry 2012 Mar; 57(3):131-2.
 

Antipsychotics for children and young adults: a comparative effectiveness review. Seida JC, Schouten JR, Boylan K, et al. Pediatrics 2012 Mar; 129(3):e771-84.
 

From ipse dixit to evidence-based guidelines: On the optimal management of Tourette syndrome. Cavanna AE, Rickards H, Worrall R, et al.  [LETTER] Eur J Paediatr Neurol 2012 Feb 14.
 

Advances in understanding and treatment of Tourette syndrome. Kevin St. P. McNaught & Jonathan W. Mink Nature Reviews Neurology 2011; 7, 667-676. ⸭
 

Treatment strategies for tics in Tourette syndrome. Eddy CM, Rickards HE, Cavanna AE Ther Adv Neurol Disord 2011 Jan; 4(1):25-45. ⸭(full article free)  ⸬
 

Treatment practices in Tourette syndrome: The European perspective. Rickards H, Cavanna AE, Worrall R. Eur J Paediatr Neurol. 2011 Dec 16. ⸭  ⸬
 

Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V J Clin Psychopharmacol 2010 Apr; 30(2):190-2. ⸭ ⸬
 

Complications of antipsychotic therapy in children with tourette syndrome. Pringsheim T, Pearce M Pediatr Neurol 2010 Jul; 43(1):17-20. ⸭  ⸬
 

Pimozide for tics in Tourette’s syndrome. Pringsheim T, Marras CCochrane Database Syst Rev 2009; (2):CD006996. ⸭  ⸬
 

Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Degrauw RS, Li JZ, Gilbert DL Pediatr Neurol 2009 Sep; 41(3):183-6. ⸭  ⸬
 

Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB Aust N Z J Psychiatry. 2008 Sep;42(9):807-13. ⸭  ⸬
 

Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Steeves TD, Fox SH. Prog Brain Res. 2008;172:495-513. ⸬
 

Tics and Tourette syndrome: diagnosis, course and treatment principles. Houeto JL, Giré P. Presse Med. 2008 Feb;37(2 Pt 2):263-70. ⸬
 

Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. Husted DS, Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK. J Psychiatr Res. 2007; 41(3-4):332-7.
 

Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: the relationship and treatment implications. Robertson MM. Eur Child Adolesc Psychiatry 2006; 15:1—11.
 

Emerging drugs in Tourette syndrome. Silay YS, Jankovic Expert Opin Emerg Drugs 2005 May; 10(2):365-80. ⸭ ⸬
 

Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature [in French] Etain B, Bonnet-Perrin E. Encephale. 2001 ;27(3):280-9.
 

Tourette syndrome, associated conditions and the complexities of treatment. Robertson MM. Brain 2000; 123:425—462.
 

Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, Leckman JF. J Child Adolesc Psychopharmacol. 1997 ;7(2):75-85.
 

Predictors of clonidine response in Tourette syndrome: implications and inferences. Lichter DG, Jackson LA. J Child Neurol. 1996 Mar;11(2):93-7. ⸭  ⸬
 

The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Singer HS, Brown J, Quaskey S, et al. Pediatrics 1995; 95:74—81.
 

Pharmacologic controversy of CNS stimulants in Gilles de la Tourette syndrome. Robertson MM, Eapen V. Clin Neuropharmacol 1992; 15:408—425.
 

Fluoxetine treatment of children and adolescents with Tourette’s and obsessive compulsive disorders: preliminary clinical experience. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL. J Am Acad Child Adolesc Psychiatry. 1990 Jan;29(1):45-8.
 

Clonidine in the treatment of Tourette syndrome: a review of data. Leckman JF, Cohen DJ, Detlor J, Young JG, Harcherik D, Shaywitz BA Adv Neurol 1982.:391-401. ⸬
 

Clonidine ameliorates Gilles de la Tourette syndrome. Cohen DJ, Detlor J, Young JG, Shaywitz BA Arch Gen Psychiatry 1980 Dec; 37(12):1350-7. ⸬